Aerpio Pharmaceuticals(AADI) - 2024 Q1 - Quarterly Results

PRESS RELEASE Exhibit 99.1 Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update Fully enrolled registration-intended PRECISION1 trial; two-thirds interim analysis planned for Q3 2024 FYARRO® sales of $5.4 million for Q1 2024, reflects distributor ordering patterns and fewer commercial patient initiations at the start of the year Conference call to be held today at 8:30 am EDT LOS ANGELES, CA, May 8, 2024 – Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-sta ...